Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
24- and 48-week MASH readouts, and it now plans a Phase 3 with a 52-week histology primary endpoint testing 1.8 mg (with 2.4 mg as an upside) as it moves into execution. Pemvidutide is a dual glucagon/GLP-1 agonist with a claimed 1:1 receptor ratio aimed at combining liver-directed antifibrotic effects and metabolic benefit, and the company emphasizes improved tolerability (EuPort domain) with lower discontinuation rates versus competitors. Phase 3 will include a biopsy-proven primary cohort plus a NIT-identified cohort, will incorporate the FDA-cleared AIM-MASH Assist tool to reduce histology variability while collecting multiple non-invasive tests (NITs) since regulators currently view NITs as premature for registrational endpoints; Altimmune also has Phase 2 AUD and ALD programs with AUD top-line data expected in Q3. Interested in Altimmune, Inc.? Here are five stocks we like better. MarketBeat Week in Review – 11/4 - 11/8 Altimmune (NASDAQ:ALT) executives highlighted rec
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]Yahoo! Finance
- Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]Seeking Alpha
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 3/17/26 - Form ARS
- 3/17/26 - Form DEF
- 3/9/26 - Form 4
- ALT's page on the SEC website